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Abstract
The SEMA3B gene is located in the 3p21.3 LUCA region, which is frequently affected in
different types of cancer. The objective of our study was to expand our knowledge of the
SEMA3B gene as a tumor suppressor and the mechanisms of its inactivation. In this study,
several experimental approaches were used: tumor growth analyses and apoptosis assays
in vitro and in SCID mice, expression and methylation assays and other. With the use of
the small cell lung cancer cell line U2020 we confirmed the function of SEMA3B as a tumor
suppressor, and showed that the suppression can be realized through the induction of apo-
ptosis and, possibly, associated with the inhibition of angiogenesis. In addition, for the first
time, high methylation frequencies have been observed in both intronic (32-39%) and pro-
moter (44-52%) CpG-islands in 38 non-small cell lung carcinomas, including 16 squamous
cell carcinomas (SCC) and 22 adenocarcinomas (ADC), and in 83 clear cell renal cell carci-
nomas (ccRCC). Correlations between the methylation frequencies of the promoter and the
intronic CpG-islands of SEMA3B with tumor stage and grade have been revealed for SCC,
ADC and ccRCC. The association between the decrease of the SEMA3BmRNA level and
hypermethylation of the promoter and the intronic CpG-islands has been estimated in renal
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primary tumors (P < 0.01). Using qPCR, we observed on the average 10- and 14-fold de-
crease of the SEMA3BmRNA level in SCC and ADC, respectively, and a 4-fold decrease in
ccRCC. The frequency of this effect was high in both lung (92-95%) and renal (84%) tumor
samples. Moreover, we showed a clear difference (P < 0.05) of the SEMA3B relative mRNA
levels in ADC with and without lymph node metastases. We conclude that aberrant expres-
sion and methylation of SEMA3B could be suggested as markers of lung and renal cancer
progression.
Introduction
Semaphorins are negative mediators of axonal guidance in the central nervous system [1].
Semaphorins comprise a large family of glycoproteins (8 classes, including 5 vertebrate classes,
of more than 30 members), but only class 3 (SEMA3) represents secreted soluble molecules.
Members of the SEMA family are differentially expressed in cancer, and either promote or sup-
press cell proliferation, migration and angiogenesis, and the induction of drug resistance. Thus,
the roles of separate members of semaphorin family can be quite different [2–9].
Class 3 semaphorins (SEMA3s, also known as collapsins) comprise one of five vertebrate
families of semaphorins and play an important role in tumor biology, including regulating cel-
lular processes, such as endothelial cell proliferation, apoptosis, migration and angiogenesis
[10]. Recently, the involvement of this protein class in carcinogenesis has been intensively stud-
ied. SEMA3s are secreted by cells of multiple lineages, including epithelial cells, neurons, and
specific tumor cells [10]. Neuropilins (NRP) represent the primary receptors of SEMA3s. The
binding of SEMA3s to NRP1/2 initiates their downstream signaling but prevents the interac-
tion between NRP1/2 and vascular endothelial growth factor (VEGF) and the subsequent in-
duction of a pro-angiogenic transcriptional program. However, it is not clear whether SEMA3s
inhibit tumor growth by competing with VEGF for neuropilins ligand-binding sites, by acting
independently of VEGF, or by a combination of these effects [10–13].
Previous studies, including ours, of human chromosome 3 in renal, lung, breast and cervical
carcinomas revealed frequent allelic losses (up to 40%) in the LUCA region (3p21.3), which har-
bors two semaphorins—SEMA3B and SEMA3F. This region (hg38/chr3: 50.0–50.5Mb) com-
prised of 445 Kb contains about 20 tumor suppressors (TSG) and TSG-candidates: RASSF1,
NPRL2, TUSC2, CACNA2D2 and others. Surprisingly, these genes playing roles in cellular pro-
cesses and exerting tumor suppression by several different ways (cell cycle block, inhibition of
angiogenesis, induction of apoptosis etc.) are located in the compact region [14–18].
Important evidence of tumor suppressor activity includes the identification of cell regulato-
ry pathways and other mechanisms that are affected by SEMA3B. Using MDA-MB435 (breast
carcinoma) and A549 (lung adenocarcinoma) cells it was previously shown that SEMA3B sup-
pressed tumor growth but triggered a pro-metastatic program by releasing interleukin 8 [19,
20]. Furthermore, it was found that the induction of apoptosis by SEMA3B in tumor cells was
mediated by inactivation of the Akt signaling pathway [21]. Therefore, it was important to fur-
ther elucidate particular aspects of SEMA3B tumor suppression.
Methylation is an important mechanism of SEMA3B gene inactivation [17, 22]. However,
the majority of previous research focused on methylation studies of the intronic CpG-island,
that was incorrectly considered as located in the promoter region.
The objective of our study was to elucidate the distinct roles of SEMA3B in tumor suppres-
sion, particularly in apoptosis and angiogenesis. Furthermore we aimed to evaluate frequencies
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of promoter (hg38/chr3: 50,267,308–50,267,797) and intronic (hg38/chr3: 50,268,972–
50,269,271) CpG-island hypermethylation correlations with SEMA3B expression, and
tumor progression in lung and renal cancers.
Materials and Methods
Cell lines
Genomic DNA was isolated from 14 cancer cell lines: 3 squamous cell lung cancers (SCLC:
ACC-LC5, NCI-N417, U2020), 2 non-small cell lung cancers (NSCLC: NCI-H157, NCI-H647)
and 9 renal cell cancers (RCC: A498, ACHN, Caki-1, Caki-2, HN-51, KH-39, KRC/Y, TK-10,
TK-164). The cell line U2020 was described earlier [23]. The ACC-LC5 cell line that carries a
deletion in 3p21.3 [24] was kindly provided by Dr. Yusuke Nakamura (University of Tokyo,
Tokyo, Japan). Renal A498, Caki1, and Caki2 and lung NCI-N417, NCI-H157, and NCI-H647
cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA).
Cell lines KRC/Y, ACHN, TK-164, HN-51, TK-10, and KH-39 were obtained from the Karo-
linska Institute (Stockholm, Sweden) cell line collection [25]. All human cell lines were grown
as monolayer cultures in IMDM/RPMI or DMEM (with 4.5 g/l glucose) supplemented with
10% fetal calf serum (FCS).
Tissue samples
In total, 70 paired tumor/normal samples of NSCLC (29 ADC and 41 SCC) and 133 clear cell
RCC (ccRCC) were obtained from the N.N. Blokhin Cancer Research Center, Russian Acade-
my of Medical Sciences (Moscow, Russia). The set of 38 NSCLC (16 ADC and 22 SCC) and
83 ccRCC was used in the methylation studies and the expression or copy number studies by
semi-quantitative RT-PCR. The additional set of 32 NSCLC (13 ADC and 19 SCC) and 50
ccRCC was used for validation by qPCR expression studies. The sample information is pre-
sented in Table 1 and S1 Table. The samples were collected in accordance with the guidelines
issued by the Ethics Committee of N.N. Blokhin Cancer Research Center, Russian Academy
of Medical Sciences (Moscow, Russia). All patients gave written informed consent (available
upon request). The Ethics Committee of N.N. Blokhin Cancer Research Center, Russian Acad-
emy of Medical Sciences, specifically approved this study. The study was performed in accor-
dance with the principles outlined in the Declaration of Helsinki. Tumor tissues and paired
morphologically normal tissues were obtained from patients after surgical resection prior to
radiation or chemotherapy and were stored in liquid nitrogen. The diagnosis was verified by
Table 1. Pathological and histological characteristics of the tumors.
Stage Number of samples
ADC SCC ccRCC
I 6/7 7/6 20/22
II 2/1 8/6 23/12
III 7/5 7/7 30/14
IV 1/0 0/0 10/2
All 16/13 22/19 83/50
Note: The slash separates the number of samples used in the methylation studies and the expression or
copy number studies by semi-quantitative RT-PCR and the number of samples used in the qPCR
expression studies.
doi:10.1371/journal.pone.0123369.t001
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histopathology, and only samples with 70–80% or more tumor cells were used in the study.
“Normal” controls were obtained at a minimum of 2 cm from the tumor and were confirmed
histologically as normal epithelial cells. Tumor specimens were characterized according to the
International System of Classification of Tumors, based on the tumor-node-metastasis (TNM)
and staging classification of the Union for International Cancer Control (UICC, version 2002)
[26] and World Health Organization (WHO) criteria classification [27, 28]. Blood samples
from 15 healthy donors were also used in the study.
SCID mice
Twelve SCID mice were used in the experiments. The mice were obtained from Scanbur (Sol-
lentuna, Sweden). Animal euthanasia was performed by CO2 asphyxiation followed by cervical
dislocation. This study was carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals (NRC 2011), the European Convention for
the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes,
Council of Europe (ETS 123), and the guidelines of the North Stockholm Ethical Committee
for Care and Use of Laboratory Animals. The experiments with the SCID mice were approved
by the North Stockholm Ethical Committee.
Transfection and selection of stably transfected SEMA3B-U2020 cell
clones
The cDNA encoding the SEMA3B gene was cloned into an episomal tetracycline—regulated
vector, pETE. The resulting plasmid was sequenced. To obtain stable cell clones expressing
SEMA3B, U2020 cells (SCLC) were transfected with empty pETE or pETE/SEMA3B plasmid
DNA (0.5 mg DNA per well) in 12-well plates using Lipofectamine and Plus Reagent (Invitrogen,
CA, USA) according to the manufacturer’s protocol. Transiently transfected pETE/SEMA3B-
U2020 and pETE-U2020 cells were cultured for 2–3 weeks in IMDMmedium containing Bsd
(5 μg/ml) to select stable clones. The expression of SEMA3Bwas regulated by doxycycline.
Colony formation assay
Transiently transfected U2020 cells (with pETE and pETE/SEMA3B) were stripped 24–48 h
after transfection and plated on 100 mm2 cell culture dishes at a density of 500–1000 cells per
plate. After selection with Bsd (5 μg/ml), Giemsa-stained colonies were photographed and
counted using Quantity One software (version 4.4.0; Bio-Rad, Hercules, CA, USA). Cell viabili-
ties were estimated by FACS analysis with propidium iodide (PI-FACS), following the manu-
facturer’s guidelines (FACSCalibur, BD Bioscience).
Tumor growth in SCID mice
The tumorigenicity of pETE/SEMA3B-transfected U2020 and empty pETE-transfected U2020
cells (control) was assessed by subcutaneous injecting the cells into 6–8-week-old SCID mice
as previously described [29]. The cells were collected by centrifugation at 800 rpm for 2 min
and resuspended in serum-free IMDMmedium at a concentration of 2–3×106 cells per 100 μl
injection. The cells were embedded into a Matrigel matrix (BD Biosciences, Erembodegem,
Belgium) according to the manufacturer’s protocol. The mice were observed for tumor forma-
tion twice per week and the tumor size was measured using calipers. Then we used the multi-
gene inactivation test (MGIT) for three genes (ZMYND10/BLU, TUSC2/FUS1 and SEMA3B)
in SCID mice. MGIT is based on the monitoring of tumor suppressor candidate gene inactiva-
tion in cells and tumors. It was accomplished according to a published method [29, 30]. Briefly,
Tumor Suppressor Function of the SEMA3BGene in Lung and Renal Cancers
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U2020 cells were transfected either with pETE/SEMA3B, pETE/ZMYND10, pETE/TUSC2 or
empty pETE plasmids. Mixes of cell clones were subcutaneously injected in SCID mice. Subse-
quently, if a tumor is formed, the expression of SEMA3B, ZMYND10 and TUSC2 is evaluated.
The knock-down of the genes suggests their importance for tumor suppression.
Immunohistochemical analysis of SCLC tumor cell line U2020 and tumor
angiogenesis in SCID mice
The plasmid pETE/SEMA3Bwas introduced into SCLC cell line U2020, which constitutively pro-
duced a tetracycline transactivator (tTA) [29]. The resulting sub-line was inoculated subcutane-
ously into SCIDmice. The mice were given drinking water with doxycycline (+dox, gene is OFF)
or without (−dox, gene is ON). The mice were euthanized after 1 month. The tumors or places of
cell injections were excised and embedded with paraffin. The sections were 5 μm in thickness.
Paraffin was dissolved in xylene (Sigma-Aldrich, St. Louis, MO, USA), and the tissue sections
were treated sequentially with 99, 95, 75 and 30% ethanol. Epitopes were recovered by heating in
a microwave oven for 5 min in citrate buffer. Anti-CD31mouse antibody, together with rabbit-
anti-mouse FITC-conjugated secondary antibody (Dako, Karlstrup, Denmark), was used to stain
microvessels. The TUNEL assay (In Situ Cell Death Detection Kit, Boehringer Mannheim, Ger-
many) for the detection of apoptosis was performed according to the manufacturer’s protocol.
DNA and total RNA isolation, reverse transcription-PCR
Nitrogen-frozen tissues were disrupted using a Mikro-Dismembrator (Sartorius, Germany).
The DNA from human tissues and cell cultures was isolated by phenol extraction according to
the standard protocols. Total RNA was isolated using the RNeasy mini kit as recommended by
Qiagen (Netherlands). Purified RNA was quantified using NanoDrop-1000 (NanoDrop Tech-
nologies Inc., DE, USA). RNA quality was assessed using 28S and 18S rRNA bands after elec-
trophoresis in a 1% denaturing agarose gel and analyzed using a Bioanalyzer 2100 (Agilent
Technologies, CA, USA). The lack of DNA contamination was checked by semi-quantitative
PCR with primers for the main histocompatibility complex I gene (MHCI, designed using Vec-
tor NTI, see S2 Table). All RNA samples were treated with RNase-free DNase I (Fermentas,
Lithuania). RNA samples containing over 0.1% DNA were discarded. The cDNA was synthe-
sized from 1 μg of total RNA using M-MuLV reverse transcriptase and random hexamers, ac-
cording to the standard manufacturer’s protocol (Fermentas, Lithuania).
Bisulfite sequencing of the promoter CpG-island of SEMA3B gene
Bisulfite DNA conversion was conducted as described in [31, 32] with the use of 1–2 μg DNA
(lung and renal cell lines and tumor/normal tissues). The modified DNA was purified using a
JETquick PCR Purification Spin Kit (Genomed, Sweden). Modified DNA was maintained at
-20°C and used as a template for PCR with the designed primers (listed in S2 Table), whose
product was sequenced. Amplification of the SEMA3B promoter CpG-island fragment was
performed in a 50 μl reaction mixture containing PCR buffer (67 mM Tris-HCl pH 8.8, 16.6
mM ammonium sulfate, 0.01% Tween 20); 2.0 mMMgCl2; 0.25 mM of each dNTP; 25 pM of
each primer; 1 unit Hot Start Taq DNA polymerase (SibEnzyme, Russia); and 5–20 ng of modi-
fied DNA in a DNA Engine Dyad Cycler (Bio-Rad, United States) using the following program:
95°C, 5 min; 35 cycles of 95°C, 15 s; 62°C, 30 s; 72°C, 30 s and 72°C, 7 min. The PCR amplified
product was purified using 1.5% agarose gel electrophoresis and the JETquick Gel Extraction
Spin Kit (Genomed, Sweden). For sequencing, 5–10 ng of the purified DNA fragment and 25
pM of one of the primers were used. Sequencing was conducted using an automatic sequencing
machine (Beckman-Coulter).
Tumor Suppressor Function of the SEMA3BGene in Lung and Renal Cancers
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Methylation specific PCR (MSP)
The bisulfite-treated DNA, dissolved in twice-distilled water, was also used as a template for
MSP. The PCR conditions and primers for the methylated and unmethylated allele of intronic
[17] and promoter (designed by DNASTAR Lasergene 2000 program) CpG-islands are given
in S2 Table. In case of the promoter CpG-island, 6 CpG-dinucleotides were analyzed (2 by the
forward primer and 4 by the reverse), and in case of the intronic—3 (1 by the forward primer
and 2 by the reverse). PCR was performed on a DNA Engine Dyad Cycler amplifier (Bio-Rad,
United States) using the following program: 95°C, 5 min; 35 cycles of 95°C, 10 s; Tann (see S2
Table), 20 s; 72°C, 30 s and 72°C, 3 min. The absence of PCR product on unconverted DNA
was checked for each pair of primers. DNA of the human fibroblast cell line L-68 served as an
unmethylated allele control; L-68 SssI DNA from L-68 fibroblasts treated with SssI methyl-
transferase (SibEnzyme, Russia) served as a positive control for 100% methylation.
Semi-quantitative RT-PCR
To control the reverse transcription, primers for the transcript of the beta2-microglobulin
(B2M) gene were used [33]. Semi-quantitative RT-PCR was performed with equal quantities
of cDNA using the primers and conditions listed in S2 Table. Multiplex PCR with primers to
the SEMA3B [17] and B2M genes was performed under conditions optimized for the SEMA3B
primers, and the concentration of B2M primers was 1.5 times lower. The products of the
RT-PCR were separated on 2% agarose gels, and the band pattern was analyzed using GelIma-
ger software (DNA Technology, Russia). A semi-quantitative copy number assay for the mark-
ers of LUCA region was used as described elsewhere [14].
qPCR
Quantitative PCR was performed with the primers and TaqMan probes listed in S2 Table using
a 7500 Real-Time PCR System (Applied Biosystems, CA, USA). Each reaction was repeated
three times. The nucleotide sequences of the amplicons were verified by sequencing in a 3730
DNA Analyzer automated sequencer (Applied Biosystems, CA, USA). QPCR data were ana-
lyzed using the reference genes GAPDH, GUSB and RPN1 [34] and the relative quantification
or ΔΔCt-method as described earlier [35]. At least 2-fold mRNA level changes were considered
as significant because of mRNA level variability of the reference genes.
Statistical analysis
The nonparametric Wilcoxon test was used to compare mRNA expression differences in the
target and reference genes in the ccRCC and NSCLC samples. Kruskal-Wallis and Mann-Whit-
ney rank-sum tests, Fisher’s exact test and χ2 criteria were used for analysis of mRNA level and
methylation status changes in ccRCC and NSCLC groups with different pathological and histo-
logical characteristics. Student's t-test was used to compare the data obtained for groups of rep-
licates. P-values 0.05 were considered statistically significant. Spearman’s rank correlation
coefficient (rs) was used for revealing correlations.
Results
In vitro growth suppression of SCLC cells U2020 by SEMA3B
The small-cell lung carcinoma cell line U2020 was transfected with pETE/SEMA3B or pETE as
the control. The transfected cells were cultured for 15 days. The growth rate of U2020 cells ex-
pressing SEMA3B was lower than the control (P< 0.01 since the day 5, see Fig 1A). The colony
formation assay showed that the number of colonies of U2020 cells containing pETE/SEMA3B
Tumor Suppressor Function of the SEMA3BGene in Lung and Renal Cancers
PLOS ONE | DOI:10.1371/journal.pone.0123369 May 11, 2015 6 / 21
was lower after re-expression of the doxycycline-suppressed SEMA3B gene in comparison to
the control cells (890 ± 60 vs 190 ± 40, P< 0.01, Fig 1B). Based on PI-FACS analysis, the abun-
dance of apoptotic and necrotic cells expressing SEMA3B (without doxycycline) was increased
significantly in comparison with SEMA3B-off cells (with doxycycline): from (7±2)×102 to (49
±5)×102, P< 0.01, see Fig 1C. Taken together, these data suggest that SEMA3B is the inhibitor
of human SCLC cells growth via induction of apoptosis in vitro.
Multi-gene inactivation test in SCID mice
We have previously reported that the GIT technique allows for the efficient and controlled in-
duction of various genes in cells [29, 30]. For the MGIT experiment, we used the SCLC cell line
U2020 for the conditional expression of three TSG-candidates located in 3p21.3: ZMYND10
(BLU), TUSC2 (FUS1) and SEMA3B. Mixes of cell clones carrying different genes were inocu-
lated subcutaneously into six-week-old SCID mice using a Matrigel (basement membrane ma-
trix) implantation technique in the absence of doxycycline (the genes were ON).
A PCR-based comparison of SCID mice tumors and primary cell clones showed unequivo-
cally that SEMA3B was selectively knocked-down in all three tumors grown in vivo (see sam-
ples 8–10 in Fig 2), whereas the expression of ZMYND10 and TUSC2 genes did not change
under these conditions. These two genes most likely did not antagonize the tumor growth of
U2020 cells in SCID mice (we leave this question open because the search for mutation through
retained genes was not included in the MGIT). These data suggest that SEMA3B is a growth in-
hibitor of human SCLC cells in vivo.
Fig 1. In vitro growth of U2020 cells (U7111 clone) depends on the expression of SEMA3B. A—The
growth rate of U2020 cells: dashed line with squares—U7111 clone with pETE/SEMA3B, solid line with
circles—U2020 cells with pETE (control); B—colony formation assay; C—PI-FACS analysis of cells with and
without expression of SEMA3B. Mean values ± standard deviations for 4 replicates are represented in
each case.
doi:10.1371/journal.pone.0123369.g001
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Effect of SEMA3B transgenes on tumor growth in SCID mice and
angiogenesis
The U2020 sub-line with conditional SEMA3B expression under doxycycline control was inoc-
ulated in SCID mice subcutaneously. Four mice received doxycycline in drinking water (+dox
mice, control) and five were not administered doxycycline (-dox mice). The onset of solid tu-
mors actively expressing SEMA3B was not observed in 4 out of 5 cases (Fig 3, red line). In the
fifth—dox mouse active tumor growth (Fig 3, yellow line) began one week later compared to
the control (Fig 3, blue line), in spite of the presence of SEMA3B in the construct. However, the
Fig 2. Absence of SEMA3B expression in tumors grown in vivo. Electropherogram of multiplex PCR from
plasmids, clones and SCID mice tumors of three genes. M—marker, 1—PCR from plasmid pETE/SEMA3B,
2—PCR from plasmid pETE/TUSC2, 3—PCR from plasmid pETE/ZMYND10, 4—PCR from U7111/SEMA3B
cell clone 1, 5—PCR from U7111/TUSC2 cell clone 3, 6—PCR from U7111/ZMYND10 cell clone 4, 7—mixed
cell clones, 8—PCR from tumor 1, 9—PCR from tumor 2, 10—PCR from tumor 3, 11—negative control.
doi:10.1371/journal.pone.0123369.g002
Fig 3. Inhibition of tumor growth by SEMA3B re-expression. The growth rate of U2020 cells (U7111
clone) in SCID mice: blue line—U2020 cells without SEMA3B expression (+ doxycycline, 4 mice), red and
yellow line—U2020 cells with SEMA3B expression (- doxycycline, 4 mice and 1 mouse respectively). *—no
expression of SEMA3B gene according to the Northern blot (data not shown). One +dox and one—dox mice
were withdrawn from the study after one month.
doi:10.1371/journal.pone.0123369.g003
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expression of the SEMA3B gene was not detected in this tumor according to the Northern blot
analysis (data not shown) suggesting loss of SEMA3B in these cells. The tumors (observed in
SEMA3B-OFF mice) had areas of active cell proliferation, in contrast to the tissues taken from
sites of cell injections (in SEMA3B-ON mice), in which abundant fibrous and poorly differenti-
ated cellular stroma and necrotic areas were observed. These data demonstrate the possibility
of SEMA3B tumor suppression activity in SCID mice.
Tissues from two sites of U2020 cells inoculation were analyzed using CD31 staining and
TUNEL assay: one SEMA3B-negative (Fig 4A and 4B) and one SEMA3B-positive (Fig 4C and
4D) mouse. Anti-CD31 mouse antibodies were used to stain blood microvessels. A very few
number of microvessels was detected in SEMA3B-positive tissues. A fragment containing one of
the microvessel-like objects is shown at Fig 4C. Microvessel signal (green channel) was co-local-
ized with signal from erythrocytes (red channel) resulting to yellow colored areas in Fig 4A.
However, SEMA3B-negative solid tumors demonstrated abundance of elongated, compressed
blood ducts with fluorescence typical to epithelia. These tumor ducts were also co-localized with
erythrocytes (Fig 4A). This could support a role of SEMA3B as inhibitor of angiogenesis. How-
ever, further experiments on the extended sampling are needed to prove this suggestion.
We hypothesized that the SEMA3B-positive cells in the areas without blood vessels and
erythrocytes were undergoing cell death. To test this hypothesis, sections of the same tissue
fragments were analyzed by a TUNEL assay, a technique enabling detection of apoptotic cells.
(Fig 4B, 4D). A huge area of apoptotic cells was observed in SEMA3B-positive tissue sample
whereas no apoptotic area was seen in SEMA3B-negative tumors. In this case, we assumed that
the expression of SEMA3B suppressed tumor growth in vivo, likely by the induction of apopto-
sis. Inhibition of angiogenesis could be suggested also.
Fig 4. Tumor sections from SCIDmice. (A, B)—SEMA3B is OFF (mouse received doxycycline in drinking
water). (C, D)—SEMA3B is ON (mouse were not administered doxycycline). (A, C)—staining with anti-CD31
to monitor blood vessels (green signal). When SEMA3B is OFF, areas filled with erythrocytes (red signal) are
seen. Yellow signal indicates co-localization of green and red signals. Blue signal corresponds to DNA. (B, D)
—TUNEL assay. Notice the area with apoptotic cells (green signal) where the SEMA3B gene was expressed.
doi:10.1371/journal.pone.0123369.g004
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Methylation of the promoter and intronic SEMA3B CpG-islands in lung
and renal cell lines and primary tumors by bisulfite sequencing and
methylation-specific PCR
The SEMA3B gene is comprised of 18 exons and contains two CpG-islands: one is located in the
promoter region (1-st CpG-island, hg38/chr3: 50,267,308–50,267,797, 22 CpG-dinucleotides)
and the other one in the first intron (2-nd CpG-island, hg38/chr3: 50,268,972–50,269,271, 12
CpG-dinucleotides). We analyzed the methylation profile of 16 CpG-dinucleotides of the pro-
moter CpG-island in 5 lung cancer cell lines (3 SCLC and 2 NSCLC) and 12 NSCLC primary tu-
mors using bisulfite sequencing (5 ADC and 7 SCC, see Fig 5A). Dense methylation (> 40% of
the analyzed CpGs were methylated) of the promoter CpG-island of the SEMA3B gene was ob-
served in 2 of 3 SCLC cell lines, but in none of the NSCLC cell lines (NCI-H157 and NCI-H647).
However, in all 7 SCC primary tumors and in 2 of 5 ADC primary tumors, methylation was de-
tected in 2–12 of the CpGs. In addition, we examined the methylation profile in 9 renal cancer
cell lines and 25 ccRCC primary tumors (Fig 5B). Dense methylation of the promoter CpG-
island was observed in 8 of 9 cell lines and 11 of 25 ccRCC primary tumors. Among matched his-
tological normal tissues, methylated CpGs were detected only in 2 of 25 ccRCC cases and in
none of 12 NSCLC cases (Fig 5A and 5B).
Next, we evaluated the methylation frequencies of both CpG-islands of the SEMA3B gene
by the MSP method using a representative set of primary tumors. The methylation frequency
of the promoter CpG-island was 44% (7/16) in ADC, 45% (10/22) in SCC and 52% (43/83) in
ccRCC. The intronic CpG-island was methylated slightly less than the promoter island in both
histological types of NSCLC (ADC −38%, 6/16; SCC −32%, 7/22) and in ccRCC (39%, 32/83;
Table 2). The methylation frequencies of both islands were significantly higher in tumor tissues
than in paired histologically normal tissues (P 0.04, see Table 2). Thus, the methylation of
both CpG-islands of the SEMA3B gene is a hallmark of lung and renal cancer. As expected, the
methylation of neither the 1-st nor the 2-nd SEMA3B CpG-island was detected in any DNA
samples isolated from blood lymphocytes of healthy donors (n = 15). The MSP data were in
agreement with the bisulfite sequencing results for each type of cancer investigated.
The use of a representative set of primary tumors allowed us to reveal possible correlations
between the methylation frequency of the promoter and intronic CpG-islands with the patho-
logical and histological parameters of the tumors. Advanced ccRCC and NSCLC tumors had a
higher frequency of CpG-island methylation compared to the early stages (Tables 2 and 3).
The strongest correlation was shown for SCC (Spearman’s rank correlation coefficients were
equal 0.37, P = 0.09, and 0.60, P< 0.01, for the 1-st and for the 2-nd CpG-island, respectively).
A positive correlation was observed between tumor grade and the frequency of CpG-island
methylation for NSCLC and ccRCC (Table 3). This correlation was stronger than the correla-
tion between tumor stage and the frequency of CpG-island methylation for both histological
types of NSCLC and almost equal to those for ccRCC (Table 3). The strongest correlation was
shown for SCC (0.49, P = 0.02, and 0.68, P< 0.01, for the 1-st and for the 2-nd CpG-island, re-
spectively). These results suggest that methylation of both SEMA3B CpG-islands is a frequent
event in renal and lung cell lines and primary tumors and contributes to the progression of tu-
mors of these locations, especially in the lung.
Correlation between methylation status of two CpG-islands and
SEMA3B gene expression level in ccRCC tumors
To investigate the consequences of CpG-island methylation, the mRNA level in 48 ccRCC
samples was evaluated by semi-quantitative PCR. In ccRCC samples, the expression of
SEMA3B was 5–1000 times lower than the matched normal samples in 24 of 48 cases (Fig 6A).
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In 4 cases, a 5-300-fold up-regulation of expression was observed. No correlation between
mRNA level changes and stage, grade or presence of metastases was observed.
Next, we compared the changes in mRNA levels of the SEMA3B gene in ccRCC tumors
(semi-quantitative PCR data) with the methylation status of two CpG-islands (methylation-
specific PCR data). Methylation of the promoter CpG-island was observed in 27 of 48 (56%)
cases and methylation of the intronic CpG-island—in 19 of 48 (40%) (Fig 6B). As shown in
Fig 6A and 6B, both islands were methylated primarily in the ccRCC samples with decreased
Fig 5. Methylation profile of the promoter CpG-island of the SEMA3B gene in lung (A) and renal (B) cancer cell lines and primary tumors. Bisulfite
sequencing data, 16 CpG-dinucleotides (2–17) of the CpG-island are given. Grey squares showmethylated CpG-dinucleotides, white squares—
unmethylated. Numbers of primary tumors correspond to those in S1 Table. The bold numbers of CpG-dinucleotides (3–4 and 9–12) indicate the location of
the primers that were used for MSPmethod.
doi:10.1371/journal.pone.0123369.g005
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SEMA3B expression. The Spearman’s correlation coefficient between expression level down-
regulations and methylation status was equal to 0.50 (P< 0.01) for the 1-st CpG-island and
0.25 (P< 0.01) for the 2-nd CpG-island. These data suggest that inactivation of SEMA3B in
carcinomas could be associated primarily with methylation of the promoter CpG-island.
Amplifications and deletions of the SEMA3B gene can contribute to
mRNA level alterations in ccRCC
A correlation between changes in SEMA3BmRNA expression and the methylation status of its
promoter CpG-island was shown in ccRCC, but for several samples, significant aberrations in
expression were not associated with methylation of either the 1-st or the 2-nd CpG-island. In
one sample, a 100-fold up-regulation was observed when both CpG-islands were methylated.
Consequently, we investigated an alternative mechanism of expression regulation, copy number
alterations, by semi-quantitative PCR. The increase in SEMA3BmRNA level in ccRCC samples
#9 and #36 (300- and 100-fold up-regulation, respectively) was associated with amplification of
Table 2. Methylation frequencies of two CpG-islands of the SEMA3B gene in NSCLC (ADC and SCC) and ccRCC in groups of samples with differ-
ent pathological and histological characteristics.
Stage ADC SCC ccRCC
1-st CpG 2-nd CpG 1-st CpG 2-nd CpG 1-st CpG 2-nd CpG
T N T N T N T N T N T N
I 33% 0% 33% 0% 14% 14% 0% 0% 40% 0% 45% 0%
(2/6) (0/6) (2/6) (0/6) (1/7) (1/7) (0/7) (0/7) (8/20) (0/20) (9/20) (0/20)
II 50% 0% 50% 0% 75% 13% 38% 0% 44% 4% 30% 9%
(1/2) (0/2) (1/2) (0/2) (6/8) (1/8) (3/8) (0/8) (10/23) (1/23) (7/23) (2/23)
III 43% 14% 29% 0% 43% 0% 57% 0% 60% 3% 33% 17%
(3/7) (1/7) (2/7) (0/7) (3/7) (0/7) (4/7) (0/7) (18/30) (1/30) (10/30) (5/30)
IV 100% 0% 100% 0% - - - - 70% 10% 60% 0%
(1/1) (0/1) (1/1) (0/1) (7/10) (1/10) (6/10) (0/10)
All 44% 6% 38% 0% 45% 9% 32% 0% 52% 4% 39% 8%
(7/16) (1/16) (6/16) (0/16) (10/22) (2/22) (7/22) (0/22) (43/83) (3/83) (32/83) (7/83)
P = 0.04 P = 0.02 P = 0.02 P = 0.01 P = 6×10–13 P = 6×10–6
Note: MSP data. 1-st CpG—promoter CpG-island; 2-nd CpG—intronic CpG-island; T—primary tumors; N—morphologically normal (conventional “normal”)
tissues paired to tumor tissues. The P-values show the signiﬁcance of the methylation frequencies distinction between tumor and normal tissues (Fisher’s
exact test and χ2 criteria).
doi:10.1371/journal.pone.0123369.t002
Table 3. Correlations between the frequency of CpG-islandmethylation and tumor stage or grade.
Feature ADC SCC ccRCC
1-st CpG 2-nd CpG 1-st CpG 2-nd CpG 1-st CpG 2-nd CpG
Stage rs 0.36 0.30 0.37 0.60 0.34 0.21
P 0.17 0.26 0.09 < 0.01 < 0.01 0.05
Grade rs 0.46 0.37 0.49 0.68 0.33 0.33
P 0.07 0.16 0.02 < 0.01 < 0.01 < 0.01
Note: Based on MSP data. 1-st CpG—promoter CpG-island; 2-nd CpG—intronic CpG-island; rs—Spearman’s rank correlation coefﬁcient; P—p-value.
doi:10.1371/journal.pone.0123369.t003
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the 5’Sema5 marker [14] (Fig 6A and 6C). A five-fold increase in mRNA level in ccRCC sample
#83 was associated with amplification of the D3S1573 marker (data not shown). Decreased
SEMA3B expression (100–1000 times) in ccRCC samples #8, #14, #15, #44 and #71 was associ-
ated with hemi- or homozygous deletions of the 5’Sema5 marker (Fig 6A and 6C). A hemizy-
gous deletion was observed in sample #34 with 5-fold down-regulation and no methylation. The
Spearman’s correlation coefficient between expression level alterations and copy number
changes was equal to 0.61 (P< 0.01) Thus, in addition to the epigenetic modifications, genetic
events (e.g., deletion or amplification of the SEMA3B gene locus) can also contribute to the al-
teration of SEMA3B gene expression in tumors. However, in samples #39 and #61, with 4-5-fold
down-regulation, and sample #17, with a 10-fold up-regulation, no copy number changes were
observed. We propose that other mechanisms may be responsible for these mRNA level alter-
ations; for example, regulation via miRNA.
Quantitative evaluation of SEMA3B expression in lung and renal tumors
To confirm the mRNA level differences, we performed qPCR analysis on an additional set of
lung and renal tumors (Table 1). We found a noticeable (up to 300 times) and frequent (94%,
30/32) down-regulation of SEMA3B gene expression in NSCLC primary tumors using qPCR
(Fig 7A). The overall frequency and extent of the decrease in SEMA3BmRNA level was similar
in the tumors of the two main histological types of NSCLC; ADC and SCC. An average 10-fold
decrease and 92% (12/13) was observed in ADC, and a 14-fold and 95% (18/19) was observed
in SCC (Table 4). Other differences were also observed. In ADC with lymph node metastases
compared to ADC without metastases, the average mRNA level was considerably decreased
(19-fold decrease vs. 3-fold, P< 0.05), but in SCC, significant expression down-regulation was
observed in the early stages of tumor development.
Fig 6. SEMA3B gene expression level (A), copy number (C) andmethylation status of its two CpG-islands (B) in the same ccRCC samples. Semi-
quantitative PCR (A, C) and MSP (B) data. Numbers of primary tumors correspond to those in S1 Table and Fig 5B. (A) Light grey columns—samples without
metastases, dark grey columns—samples with lymph node or distant metastases. (B) 1-st CpG—promoter CpG-island, 2-nd CpG—intronic CpG-island.
Grey squares showmethylated CpG-islands, white squares—unmethylated. (C) Grey squares show hemi- or homozygous deletions of the 5’Sema5 marker,
black—amplification, white squares—retention. Assessed mean values ± error bars are represented in the “A” part.
doi:10.1371/journal.pone.0123369.g006
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In ccRCC samples we also observed frequent (84%, 42/50) SEMA3B gene expression down-
regulation (4-fold on average, Fig 7B). However, these values were not as high as for NSCLC.
No correlation was observed between mRNA level changes and stage (Table 4) or the presence
of metastases (Fig 7B).
Based on these results, we conclude that significant and frequent decreases in SEMA3B
mRNA level are in agreement with the semi-quantitative PCR and methylation data and con-
firm that SEMA3B down-regulation is a frequent event both in NSCLC and ccRCC. However,
the frequency of down-regulation was higher than the frequency of CpG-island methylation
(Tables 2 and 4). Thus, other mechanisms of inactivation are also likely contributors: for ex-
ample, deletions in renal, lung and breast cancers, according to our results and the data of
others [14, 15, 17].
Fig 7. Relative mRNA level of the SEMA3B gene in NSCLC (A) and ccRCC (B).QPCR data, additional samplings. Light grey columns—samples without
metastases, dark grey columns—samples with lymph node or distant metastases. The numbers of primary tumors correspond to those in S1 Table. Mean
values ± standard deviations for 3 replicates are represented.
doi:10.1371/journal.pone.0123369.g007
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Discussion
The SEMA3B gene is located in the LUCA region (3p21.3) that harbors 19 genes, the majority
of which are involved in carcinogenesis [16, 36–38]. Some of these genes, e.g., RASSF1, NPRL2,
and SEMA3B, suppress the growth of tumor cells in vitro and in vivo [36–38]. However,
SEMA3Bmay have both tumor-suppressive and pro-invasive properties. It has been reported
that SEMA3B is dramatically down-regulated in the cell line H460-M, derived from the large
cell lung tumor cell line NIH-H460, which induces spontaneous metastasis in nude mice [39].
On the other hand, it is highly expressed in many invasive and metastatic human cancers; for
example, colorectal carcinoma, neuroblastoma, melanoma and acute myeloid leukemia [20,
40]. SEMA3B induces apoptosis and the production of interleukin 8 by tumor cells by initiating
the p38-mitogen-activated protein kinase pathway. In turn, the release of interleukin 8 induces
the recruitment of tumor-associated macrophages, which may lead to metastatic dissemination
of the tumor [20, 41]. In this study, we confirmed the tumor-suppressive activity of SEMA3B
both in vitro (U2020 SCLC cells) and in vivo (SCID mice models, by both tumor growth assay
and multi-gene inactivation tests). Our studies in vitro are in agreement with previous research
in NSCLC, breast and ovarian ADC cell lines [19, 22, 42]. However, in this study, the suppres-
sive effect of SEMA3B in vivo has been shown for the first time.
Semaphorins 3 encode proteins with axonal guidance properties that generally affect the
motility and migration of tumor and endothelial cells by inducing a collapse of the actin cyto-
skeleton via binding to neuropilins/plexins complexes [43, 44]. Earlier, the class-3 semaphorins
were implicated in tumor progression and metastasis [39, 45, 46]. However, tumor suppression
properties of distinct semaphorins differ across various cancer types. For example SEMA3D
and SEMA3E displayed strong inhibitory effect on the glioblastoma cells whereas SEMA3A
and SEMA3B expression just caused persistent cell shape contraction [47]. On the other hand,
SEMA3B was previously demonstrated to inhibit proliferation of breast and lung cancer cell
lines in vitro [20, 22]. Some studies suggest that the mechanism of the tumor- and angio-sup-
pressive properties of SEMA3 proteins is competition between SEMA3 and VEGF for binding
to neuropilin receptors [19, 48]. Other studies reveal SEMA3 growth-inhibitory properties in-
dependent of competition with VEGF [10]. Several studies indicate that SEMA3A and
SEMA3F are potent inhibitors of metastasis and angiogenesis [10, 49, 50]. Semaphorins 3 were
suggested as potential angiogenesis inhibitory agents for triple negative breast cancer treatment
Table 4. Frequency andmRNA level changes of the SEMA3B gene in NSCLC (ADC and SCC) and ccRCC in groups of samples with different patho-
logical and histological characteristics.
Stage Median of R, n-fold decrease* Frequency of R decrease, %
ADC SCC ccRCC ADC SCC ccRCC
I 3 19 4 86 100 77
(1–102) (7–28) (1–45) (6/7) (6/6) (17/22)
II 10 11 6 100 83 100
(1–36) (2–25) (1/1) (5/6) (12/12)
III+IV 21 15 3 100 100 81
(12–36) (2–3×102) (1–11) (5/5) (7/7) (13/16)
All 10 14 4 92 95 84
(1–102) (1–3×102) (1–45) (12/13) (18/19) (42/50)
Note: QPCR data. R—relative mRNA level.
*—in parentheses a range of mRNA level changes is shown.
doi:10.1371/journal.pone.0123369.t004
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[51]. However, Varshavsky et al. have determined that point mutations at the cleavage site of
SEMA3B can inhibit angiogenesis in vitro and in vivo [52]. Joseph et al. demonstrated that
forced expression of SEMA3B, but not SEMA3F, inhibited the viability of ovarian cancer cells
lines in vitro, and presence of SEMA3F but not SEMA3B significantly inhibited the production
of endothelial tubes formed by normal human umbilical vein endothelial cells (HUVEC) in
vitro [53]. In this study, using PI-FACS we have shown that tumor growth suppression by
SEMA3B is associated with induction of apoptosis in vitro. In addition, we have suggested that
SEMA3B could be able to induce apoptosis and, possibly, inhibit angiogenesis in vivo, which
was previously demonstrated only in vitro [20, 22].
One of the hallmarks of tumor-suppressor genes is the down-regulation of their expression
in various tumors at the mRNA or protein level. Inactivation of suppressor genes in tumors
can be caused by methylation of their promoter regions. Hypermethylation often reduces the
mRNA levels not only of SEMA3B but also of some other genes of the LUCA region in tumors;
e.g., RASSF1A, BLU, and CACNA2D2 [36–38]. SEMA3Bmethylation has been observed in
various types of cancer, including lung, liver, gallbladder, gastric, breast and oral carcinomas,
and neuroblastoma [17, 54–61]. However, these studies included only the CpG-island, which,
according to the NCBI database (http://www.ncbi.nlm.nih.gov/), belongs to the first intron
(+1350..+1700 bp from SEMA3B 5’-end) of SEMA3B. However, there is a true promoter re-
gion, which includes CpG-dinucleotides with higher density (-300..+50 bp from SEMA3B 5’-
end) and is capable of binding transcription factors, such as Lyf−1, DeltaEF−1, Tcf−11, c−Myb,
SP1, C/EBP, and AhR/Arnt (according to the recent ENCODE data, http://genome.ucsc.edu/
ENCODE/).
Here, for the first time, methylation of both intronic and promoter CpG islands has been
analyzed in 14 lung and renal cancer cell lines and representative sets of primary tumors (38
NSCLC and 83 ccRCC cases). We observed frequent methylation of intronic and promoter
CpG-islands in both lung (SCC and ADC) and renal primary tumors. In addition, the methyla-
tion frequency detected in the promoter CpG-island was higher than in the intronic island in
SCC, ADC, and ccRCC (44–52% vs. 32–39%). Thus, methylation of both promoter and intro-
nic SEMA3B CpG-islands is a feature of lung and renal tumors.
In addition, an association was observed between the decrease of the SEMA3BmRNA level
and the methylation of the promoter and intronic CpG-islands in ccRCC primary tumors (the
Spearman’s correlation coefficient was equal to 0.50 (P< 0.01) for the promoter CpG-island
and 0.25 (P< 0.01) for the intronic island). These data imply a primary contribution of pro-
moter CpG-island methylation to down-regulation of the SEMA3B suppressor gene.
The frequency of SEMA3B promoter hypermethylation (44–52%) is approximately two
times lower than the frequency of expression decreases (84–95% cases, according to semi-
quantitative PCR data) in NSCLC and ccRCC. Thus, other mechanisms could lead to SEMA3B
down-regulation. For example, we have found hemi- or homozygous deletions of the 5’Sema5
marker in some ccRCC samples. There are several reports, including ours, of chromosome 3 al-
lelic losses resulting in decreased SEMA3BmRNA levels in lung and renal tumors [14, 55]. The
impact of non-coding RNA, especially miRNA, should not be ignored; e.g., miR-137 or miR-
193a, as predicted by miRWalk (http://www.ma.uni-heidelberg.de/apps/zmf/mirwalk/).
The use of a representative set of primary tumors allowed us to reveal the correlations be-
tween the methylation frequency of both the promoter and the intronic CpG-islands of SEMA3B
with tumor stage and grade for histological types of NSCLC (SCC and ADC) and for ccRCC.
The highest Spearman’s rank correlation coefficients between mentioned features were observed
for SCC (rs was localized over the range 0.37–0.68).
SEMA3B expression was evaluated by quantitative PCR using an additional set of NSCLC
(SCC and ADC) and ccRCC samples. We observed frequent and significant SEMA3B down-
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regulation in SCC and ADC, and somewhat less in ccRCC. SEMA3B down-regulation has been
shown in lung, liver, breast, ovarian, renal and colon primary tumors using different semi-
quantitative methods [2, 62]. Down-regulation of SEMA3B gene was negatively correlated with
tumor size and gastric cancer staging [61]. Here, a large decrease of SEMA3BmRNA level in
primary NSCLC and ccRCC was shown for the first time using qPCR. We also observed an as-
sociation of the frequency and extent of the decrease in SEMA3BmRNA level with the develop-
ment of ADC metastases (P< 0.05). In SCC, we revealed 10-fold and above down-regulation
of the expression of this gene already at early stages of tumor development.
The methylation analysis revealed a significant association of SEMA3B hypermethylation
with tumor progression in terms of tumor stage and grade for both subtypes of NSCLC (SCC
and ADC) and ccRCC. Moreover, our qPCR expression studies have established a strong re-
verse correlation between the SEMA3BmRNA level and the presence of metastases in lung
ADC. Therefore, hypermethylation of SEMA3B CpG-islands could be suggested as a progres-
sion marker for ccRCC and NSCLC (especially SCC), and for the SEMA3BmRNA level as a
marker of metastasis development in lung ADC.
Other members of class 3 semaphorins also reveal distinct features, such as expression level
variations or tumor suppressive ability, depending on the tumor type or the model system.
Mouse melanoma (B16F10) cells overexpressing Sema3A show a significant inhibition of cell
motility, invasiveness and proliferation, as well as suppression of tumor growth in vivo, and an-
giogenesis and metastasis in mice models [50]. Sema3A/B/C/E are also involved in the lymph
node metastasis of prostate cancer, but they are likely to modulate the behavior of prostate can-
cer with a pro-tumor or anti-tumor effect, depending on the subtype [63].
In conclusion, our in vitro and in vivo results reveal the tumor suppressor role of SEMA3B,
which could acts by inducing apoptosis or, possibly, inhibiting angiogenesis. Our data also show
that methylation of both the promoter and intronic CpG-islands of SEMA3B is a frequent event in
ccRCC and two major histological types of NSCLC, but correlation of SEMA3B down-regulation
and hypermethylation is stronger for the promoter CpG-island. Significant decreases in the level
of SEMA3BmRNA in the majority of the lung and renal tumor samples were revealed by qPCR.
Association of SEMA3B hypermethylation and down-regulation with tumor progression could
serve as prognostic markers. An understanding of the role of SEMA3s, including SEMA3B, in car-
cinogenesis will help to use their tumor suppressive and anti-angiogenic properties for the devel-
opment of new agents for cancer therapy in future.
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